

# EPICS

## EPICS 2021 – Global Perspectives on Melanoma, Squamous Cell Carcinoma (SCC), and Basal Cell Carcinoma (BCC)

Chair: Jeffrey S. Weber, MD, PhD (US)

Saturday, June 26, 2021: 10.00 AM – 1.30 PM EST / 16.00 – 19.30 CET

### AGENDA

Time (EST)	Topic	Speaker/Moderator
10.00 AM – 10.05 AM (5 min)	<b>Introduction and Review Agenda and Framework for Meeting</b>	Jeffrey S. Weber, MD, PhD
10.05 AM – 10.15 AM (10 min)	<b>New Perspectives in Melanoma Adjuvant and Neoadjuvant Therapy</b>	Alexander Eggermont, MD, PhD
10.15 AM – 10.35 AM (20 min)	<p><b>Key Questions and Topics for Discussion</b></p> <ul style="list-style-type: none"> <li>• Were there any practice-changing data presented at EADO and ASCO?</li> <li>• What are the current and emerging roles of immunotherapy and targeted therapy in the adjuvant setting?</li> <li>• How are neoadjuvant combination strategies evolving in melanoma? <ul style="list-style-type: none"> <li>– Checkpoint inhibitor combinations</li> <li>– Targeted therapy combinations</li> </ul> </li> <li>• Is there a need for adjuvant therapy when neoadjuvant treatments induce a MPR?</li> </ul>	All
10.35 AM – 10.40 AM (5 min)	Summary of Key Takeaways	All
10.40 AM – 10.50 AM (10 min)	<b>Emerging Insights in Relapsed/Refractory Metastatic Melanoma</b>	Adi Diab, MD
10.50 AM – 11.10 AM (20 min)	<p><b>Key Questions and Topics for Discussion</b></p> <ul style="list-style-type: none"> <li>• Were there any practice-changing data presented at EADO and ASCO?</li> <li>• Are there promising agents in the PD-1–refractory metastatic melanoma setting? Role of tumor-infiltrating lymphocytes (TILs)? Others?</li> <li>• Are there promising immunotherapy agents beyond checkpoint inhibitors?</li> <li>• What have we learned from intralesional immunotherapy in metastatic melanoma?</li> </ul>	All

11.10 AM – 11.15 AM (5 min)	Summary of Key Takeaways	All
11.15 AM – 11.20 AM (5 min)	<b>Evolution of Immunotherapy for 1L Metastatic Melanoma</b>	Hussein Tawbi MD, PhD – TBC
11.20 AM – 11.35 AM (15 min)	<p><b>Key Questions and Topics for Discussion</b></p> <ul style="list-style-type: none"> <li>• Were there any practice-changing data presented at EADO?</li> <li>• Is there evidence for predictors of response and resistance to checkpoint inhibitors? Are any of them clinically relevant?</li> <li>• What are your thoughts regarding frontline trials of nivolumab in combination with other novel agents, eg, relatlimab (RELATIVITY-047 trial), IDO/PD-L1 peptide vaccine?</li> <li>• Are there biomarkers of immune-related adverse events that are clinically useful?</li> </ul>	All
11.35 AM – 11.40 AM (5 min)	Summary of Key Takeaways	All
11.40 AM – 11.45 AM (5 min)	<b>BREAK</b>	
11.45 AM – 11.50 AM (5 min)	<b>1L BRAF-Mutated Metastatic Melanoma – Strategies to Improve on MAPK-Targeted Therapies</b>	Jeffrey S. Weber, MD, PhD
11.50 AM – 12.10 PM (20 min)	<p><b>Key Questions and Topics for Discussion</b></p> <ul style="list-style-type: none"> <li>• Were there any practice-changing data presented at EADO and ASCO?</li> <li>• Is there a role for triplet therapy in <i>BRAF</i>-mutated metastatic melanoma?</li> <li>• Can immunotherapy overcome resistance to <i>BRAF</i> inhibition in <i>BRAF</i>-mutated metastatic melanoma?</li> <li>• What are the optimal sequencing strategies with immunotherapy and targeted therapies?</li> </ul>	All
12.10 PM – 12.15 PM (5 min)	Summary of Key Takeaways	All
12.15 PM – 12.25 PM (10 min)	<b>New Perspectives in the Management of SCC</b>	Omid Hamid, MD

12.25 PM – 12.45 PM (20 min)	<b>Key Questions and Topics for Discussion</b> <ul style="list-style-type: none"> <li>• Were there any practice-changing data presented at EADO and ASCO?</li> <li>• What are your views on how the management of advanced SCC is evolving?</li> <li>• Has neoadjuvant immune therapy reached the mainstream?</li> <li>• Can we define the mechanisms of resistance to immunotherapy in advanced SSC, and how to overcome them?</li> <li>• What upcoming novel therapies are likely to be useful for treating high-risk SCC?</li> </ul>	All
12.45 PM – 12.50 PM (5 min)	Summary of Key Takeaways	All
12.50 PM – 1.00 PM (10 mins)	<b>Emerging Advances in the Management of BCC</b>	Ragini Kudchadkar, MD
1.00 PM – 1.20 PM (20 min)	<b>Key Questions and Topics for Discussion</b> <ul style="list-style-type: none"> <li>• Were there any practice-changing data presented at EADO and ASCO?</li> <li>• What are your views on how the management of advanced BCC is evolving?</li> <li>• What first-line treatment options are emerging for high-risk BCC patients?</li> <li>• What is the role for immunotherapy in the treatment of BCC? Neoadjuvant or adjuvant therapy?</li> </ul>	All
1.20 PM – 1.25 PM (5 min)	Summary of Key Takeaways	All
1.25 PM – 1.30 PM (5 min)	<b>Summary, Key Takeaways, and Closing Remarks</b>	Jeffrey S. Weber, MD, PhD